Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
March 2020
-
Media ReleaseAveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,…
-
Media ReleaseNovartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic responseHydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory…
-
Key ReleaseNovartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at…
-
Media ReleaseNovartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapyInclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk…
-
Media ReleaseNovartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communitiesNovartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R…
-
Media ReleaseInternational research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in AfricaEDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million. The PAMAfrica consortium brings…
-
Key ReleaseSandoz Resolves Generic Drug Antitrust Investigation in the U.S.Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
February 2020
-
Key ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General MeetingShareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr.…
-
Key ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelleLes actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow…
-
Media ReleaseNovartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasisLXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
-
Media ReleaseNovartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
-
Media ReleaseNovartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwideBeovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…
Pagination
- ‹ Previous page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- …
- 100
- › Next page